MM-398 put on Fast Track for pancreatic cancer

PharmEngine Inc. (GreTai:4162) and partner Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) said FDA granted Fast Track designation to their MM-398 to treat metastatic pancreatic cancer in patients previously treated with gemcitabine. Merrimack plans to begin a rolling NDA submission by year end.

Merrimack has exclusive, worldwide rights to the nanoparticle liposome formulation of irinotecan from PharmaEngine outside of Taiwan, where PharmaEngine retains rights. ...